Xenon Pharmaceuticals
Burnaby
About Xenon Pharmaceuticals
Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $1.8B
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2026)
- Ticker: nasdaq:XENE
- Website: xenon-pharma.com
- Phone: (604) 484-3300
Industries & Categories
Biopharma, Biotechnology, Genetics, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/xenon-pharmaceuticals-54053 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.